×

Stocks Johnson & Johnson

  • While the Burlington Northern deal is getting a lot of attention, it has not brought pre-open trading in the S&P futures into positive territory yet. Risk aversion has become a more prominent theme since last Wednesday, when the S&P 500 dropped below its 50-day moving average for the first time since July.

  • Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.

  • We asked the traders for their favorite stocks to 'buy and hold' for the long-term. After all, good things come to those who wait!

  • Markets rose on Thursday after data showed the economy grew more than expected last quarter and jobless claims fell. How should investors be positioning their portfolios now? Dan Genter, president, CEO and CIO of RNC Genter Capital Management, and Dean Barber, founder and president of Barber Financial Group, shared their market insights.

  • Recovery sign

    As the US economic recovery looms larger, the gray cloud that has hung over the stock market for so long is finally starting to fade. Here's four sectors likely to outperform in the months and year ahead.

  • stock_chart_screen.jpg

    After a stunning and broad rebound, major indices many be range bound for awhile and the right managers could thrive with judicious stockpicking.

  • With Microsoft's earnings report this morning, two thirds of the Dow 30 have now reported.  Here is a summary of how things stand in terms of EPS and revenues.

  • earnings_central_badge.jpg

    One of the things we learned in Pfizer's earnings press release and on the conference call today is that since the start of 2008 the company has eliminated 11,200 positions. And now that the world's biggest pharmaceutical firm has gotten even bigger by swallowing Wyeth, it's going to let go even more people to help wring out about $4 billion in annual expenses by 2012.

  • Stocks opened mixed after several earnings reports beat expectations but economic numbers missed their targets. Dan Genter of RNC Genter Capital Management and Alan Gayle of RidgeWorth Capital Management shared their market outlooks.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • The positive tone set by this week's earnings reports will likely shift toward mediocrity in the upcoming week, said Charlie Smith, CIO of Fort Pitt Capital Group and Alan Valdes, vice president of Kabrik Trading.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    Meaning: shareholders. Here are two companies that delivered surprise quarters – but not in a good way.

  • The stock rally could have legs after a line of better-than-expected third-quarter earnings reports, but Art Cashin, head of floor operations at UBS, said he isn't yet convinced.

  • Vince Farrell

    The National Association of Business Economists - and don't we all want to be part of that convention at party time! - issued a report the other day that doesn't ring true to me.

  • Following my post earlier this week on the highest yielding stocks in the Dow, here is a deeper look at the dividends of the S&P 500.

  • Investors are tired of companies reporting profits due to cost cutting and layoffs. This earnings season they’re saying, where's the revenue beef?

  • What follows is a roundup of corporate earnings reports for Wednesday, Oct. 14.

  • Stocks ended mostly lower Tuesday after J&J's revenue miss stirred worries about this earnings season.

  • earnings_central_badge.jpg

    Railroad company CSX releases its third-quarter earnings Tuesday, but Donald Broughton, transportation analyst at Avondale Partners, said he wouldn't buy into the company at its current levels because of lower volumes and pricing risks associated with railroads.

  • The Fast Money traders are closely watching Intel calling this stock is a major ‘tell’ not only for tech but the broad market. What must you know?